[Skip to Content]
[Skip to Content Landing]
September 7, 1957


JAMA. 1957;165(1):91. doi:10.1001/jama.1957.02980190093027

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  In Foreign Letters in the July 13 issue of The Journal, page 1268, is a short note from France reporting on the effects of a new analgesic 2,2-diphenyl-3-methyl-4-morpholine-butyryl-pyrrolidine ( R 875), prepared by P. Janssen of Belgium. The note says, "It is not habit-forming." This product has been studied in the United States, including tests at the Addiction Research Center at Lexington, Ky., with the conclusion that it "has addiction liability at least equivalent to that of morphine (Addendum to the Minutes of the 18th Meeting of the Committee on Drug Addiction and Narcotics of the National Research Council). R 875 was placed provisionally under international narcotics control by the Commission on Narcotic Drugs of the United Nations at its 12th session, and coverage of R 875 under the U. S. Opiates Act has been recommended.

First Page Preview View Large
First page PDF preview
First page PDF preview